Compare IDEXX Laboratories, Inc. (IDXX) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Jumia Technologies AG - ADR — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Jumia Technologies AG - ADR trades at $6.4 (market cap $865.90M). The key difference: IDEXX Laboratories, Inc. is far larger — about 46.7× Jumia Technologies AG - ADR's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 1,695,227). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Jumia Technologies AG - ADR for 28 Days on average.
| IDXX | JMIA | |
|---|---|---|
Market Cap | $40.43B | $865.90M |
Volume | 692,164 | 1,695,227 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $14.60 |
52-Week Low | $504.70 | $5.69 |
Typical Hold Time | 46 Days | 28 Days |
Enterprise Value | $41.32B | $831.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
JMIA stock trades at $6.28, down 6.82% today, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $167M in 2024 to $189M in 2025 and narrowing losses. Analyst consensus remains strong with 71% buy ratings and a $12.00 price target, supported by recent $50M capital infusion and path to EBITDA breakeven.
The outlook suggests potential upside if JMIA achieves profitability targets, but risks include persistent negative margins, high P/B ratio of 975, and competitive pressures in African e-commerce. The stock offers speculative growth potential with significant execution risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
